Compare Stocks → Protect Yourself While There’s Still Time … (From Weiss Ratings) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:APTONASDAQ:ATRANASDAQ:AVRONASDAQ:RCELNASDAQ:RUBY Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPTOAptose Biosciences$1.22+5.2%$1.54$1.15▼$8.70$19.18M1.2987,380 shs104,863 shsATRAAtara Biotherapeutics$0.69-1.4%$0.72$0.20▼$3.02$82.36M0.692.65 million shs525,301 shsAVROAVROBIO$1.21+1.7%$1.27$0.57▼$1.70$54.28M1.22269,863 shs204,967 shsRCELAVITA Medical$8.52+2.7%$14.71$8.01▼$21.70$219.82M1.33213,058 shs285,974 shsRUBYRubius Therapeutics$0.06$0.04$0.00▼$0.38$5.16M2.591.15 million shs755,858 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleGrowth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPTOAptose Biosciences-4.92%-8.66%-27.50%-41.41%-83.67%ATRAAtara Biotherapeutics-2.08%+1.17%+5.87%+16.19%-74.37%AVROAVROBIO-0.42%-4.44%-5.95%-12.87%+33.15%RCELAVITA Medical-3.15%-6.43%-48.09%-50.09%-41.09%RUBYRubius Therapeutics0.00%0.00%0.00%0.00%+123.53%Protect Yourself While There’s Still Time … (Ad)The next step of the Fed's control is here. Section 702 of the Foreign Intelligence Surveillance Act was renewed for two more years and passed into law earlier this week. Allowing the Fed to tighten its grip on your personal privacy and freedom.4 simple steps to protect your privacy and money before it’s too late.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAPTOAptose Biosciences2.7251 of 5 stars3.55.00.00.03.10.00.6ATRAAtara Biotherapeutics3.307 of 5 stars3.01.00.04.70.62.50.6AVROAVROBIO1.3906 of 5 stars3.04.00.00.00.01.70.6RCELAVITA Medical1.2808 of 5 stars3.42.00.00.02.10.00.6RUBYRubius TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAPTOAptose Biosciences3.00Buy$19.801,522.95% UpsideATRAAtara Biotherapeutics2.00Hold$28.003,957.97% UpsideAVROAVROBIO2.00Hold$2.0065.29% UpsideRCELAVITA Medical2.80Moderate Buy$27.80226.29% UpsideRUBYRubius TherapeuticsN/AN/AN/AN/ACurrent Analyst RatingsLatest ATRA, AVRO, RUBY, RCEL, and APTO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/11/2024RCELAVITA MedicalBTIG ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Neutral4/3/2024APTOAptose BiosciencesPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$5.003/27/2024APTOAptose BiosciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$23.002/23/2024RCELAVITA MedicalPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$19.00 ➝ $21.002/23/2024RCELAVITA MedicalCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$22.00 ➝ $25.002/1/2024APTOAptose BiosciencesPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$12.00 ➝ $5.00(Data available from 4/26/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAPTOAptose BiosciencesN/AN/AN/AN/A($0.19) per shareN/AATRAAtara Biotherapeutics$8.57M9.61N/AN/A($0.97) per share-0.71AVROAVROBION/AN/A$0.29 per share4.15$2.13 per shareN/ARCELAVITA Medical$50.14M4.38N/AN/A$1.92 per share4.44RUBYRubius TherapeuticsN/AN/AN/AN/A$0.17 per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAPTOAptose Biosciences-$51.21M-$7.72N/AN/AN/AN/A-458.70%-205.30%5/13/2024 (Estimated)ATRAAtara Biotherapeutics-$276.13M-$2.62N/AN/AN/A-3,220.88%-783.31%-122.34%5/13/2024 (Estimated)AVROAVROBIO$12.16M-$0.10N/AN/AN/AN/A-74.86%-65.11%5/9/2024 (Estimated)RCELAVITA Medical-$35.38M-$1.40N/AN/AN/A-70.56%-54.80%-38.08%5/13/2024 (Confirmed)RUBYRubius Therapeutics-$179.67MN/A0.00∞N/AN/AN/AN/AN/ALatest ATRA, AVRO, RUBY, RCEL, and APTO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2024N/ARCELAVITA Medical-$0.26N/A+$0.26N/AN/AN/A 3/28/2024Q4 2023ATRAAtara Biotherapeutics-$0.61-$0.56+$0.05-$0.56$2.45 million$4.25 million3/26/2024Q4 2023APTOAptose Biosciences-$1.48-$1.44+$0.04-$1.44N/AN/A2/22/2024Q4 2023RCELAVITA Medical-$0.34-$0.28+$0.06-$0.28$14.10 million$14.20 millionDividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAPTOAptose BiosciencesN/AN/AN/AN/AN/AATRAAtara BiotherapeuticsN/AN/AN/AN/AN/AAVROAVROBION/AN/AN/AN/AN/ARCELAVITA MedicalN/AN/AN/AN/AN/ARUBYRubius TherapeuticsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAPTOAptose BiosciencesN/A0.780.78ATRAAtara BiotherapeuticsN/A0.720.65AVROAVROBION/A15.7815.78RCELAVITA Medical0.817.887.46RUBYRubius TherapeuticsN/AN/AN/AOwnershipInstitutional OwnershipCompanyInstitutional OwnershipAPTOAptose Biosciences26.62%ATRAAtara Biotherapeutics70.90%AVROAVROBIO62.63%RCELAVITA Medical27.66%RUBYRubius TherapeuticsN/AInsider OwnershipCompanyInsider OwnershipAPTOAptose Biosciences9.53%ATRAAtara Biotherapeutics4.50%AVROAVROBIO9.20%RCELAVITA Medical1.96%RUBYRubius Therapeutics5.30%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableAPTOAptose Biosciences3115.72 million14.22 millionNo DataATRAAtara Biotherapeutics334119.36 million113.99 millionOptionableAVROAVROBIO1344.86 million40.73 millionOptionableRCELAVITA Medical20725.80 million25.20 millionOptionableRUBYRubius Therapeutics690.48 million85.69 millionNot OptionableATRA, AVRO, RUBY, RCEL, and APTO HeadlinesSourceHeadline‘Expats’ Star Ruby Ruiz to Lead James J. Robinson’s Directorial Debut ‘First Light’ (EXCLUSIVE)yahoo.com - April 26 at 3:33 AMVacant Rubius property generating interest after 1 year on marketpbn.com - April 18 at 1:01 AMSensorium Therapeutics Appoints Sam Rasty as Chief Business Officercitizentribune.com - April 17 at 8:01 PMVacant RI biotech space, once owned by Rubius Therapeutics, offered at 'deeply discounted price'bizjournals.com - March 11 at 5:07 PMRubius Therapeutics Inc RUBYmorningstar.com - November 5 at 8:39 PM‘Like playing the lottery’: Laid-off life sciences workers give a snapshot of a cooling-down sectorbostonglobe.com - October 16 at 7:58 AMRuby Dunne Biography & Moviestribute.ca - September 22 at 6:08 PMParenting Vlogger Ruby Franke Held Without Bail on Child Abuse Chargesoxygen.com - September 14 at 8:44 PMYouTuber mom Ruby Franke arrested and charged in child abuse investigation: What to knowtoday.com - September 8 at 6:33 PMRuby Gonzalesdailynews.com - August 21 at 8:30 AMRUBY - Rubius Therapeutics, Inc.uk.finance.yahoo.com - August 2 at 2:37 AMNorth American Morning Briefing: Alphabet, -2-morningstar.com - July 25 at 7:07 AMRuby Rivera, 23ABCturnto23.com - July 1 at 12:54 AMRuby Speakingcomedy.co.uk - June 23 at 3:11 PMRubius Therapeutics Outlines Dissolution Plan, After Unsuccessful Attempt On Alternativesfinance.yahoo.com - March 2 at 1:59 AMWhatever happened to Ruby?infoworld.com - February 17 at 4:07 PMThinking about buying stock in Sorrento Therapeutics, Rubius Therapeutics, Ideanomics, SoundHound AI, or C3.ai?marketwatch.com - February 14 at 7:55 PMWhy Is Rubius Therapeutics (RUBY) Stock Up 35% Today?msn.com - February 14 at 9:54 AMThe Wrap: Ruby's moving to Congress Street, launching new French conceptyahoo.com - January 25 at 4:27 AMRuby Wax sparks concern from fans after posting video from hospital bedmirror.co.uk - January 12 at 12:51 AMRuby Wax sparks concern amongst fans with her latest appearance from a hospital bed promoting bookdailymail.co.uk - January 12 at 12:51 AMFormer Rubius CEO jumps to another Flagship spinoutfinance.yahoo.com - November 18 at 10:30 AMRubius Therapeutics lays off most of its staff, explores salefinance.yahoo.com - November 4 at 12:16 PMRubius Therapeutics Cuts Almost 85% Of Its Workforce, Starts Looking For Strategic Alternativesfinance.yahoo.com - November 3 at 1:47 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop Headlines3 Value Stocks Too Small For Buffett’s PortfolioMarch 28, 2024 12:16 PMView 3 Value Stocks Too Small For Buffett’s Portfolio3 Stocks Leading the U.S. Agriculture ComebackApril 26, 2024 10:10 AMView 3 Stocks Leading the U.S. Agriculture Comeback3 Companies Buying Back Stock Before New HighsApril 1, 2024 6:05 AMView 3 Companies Buying Back Stock Before New HighsUnited Parcel Service Is Setting Up for Another FallApril 24, 2024 6:15 AMView United Parcel Service Is Setting Up for Another FallAmazon Stock Insights & Analysis for 2024 April 22, 2024 7:13 AMView Amazon Stock Insights & Analysis for 2024 All Headlines Company DescriptionsAptose BiosciencesNASDAQ:APTOAptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies. The company has an agreement with CrystalGenomics, Inc. to research, develop, and commercialize CG026806, a non-covalent small molecule therapeutic agent, which is in preclinical stage for the treatment of acute myeloid leukemia and chronic lymphocytic leukemia/mantle cell lymphoma. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was founded in 1986 and is headquartered in Mississauga, Canada.Atara BiotherapeuticsNASDAQ:ATRAAtara Biotherapeutics, Inc. develops therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma. Its CAR T immunotherapy pipeline products include ATA2271 and ATA3271 to treat mesothelin; and ATA3219 for the treatment of B-cell malignancies, as well as ATA188 that is in Phase 2 clinical trials to treat multiple sclerosis. Atara Biotherapeutics, Inc. has a license agreement with Memorial Sloan Kettering Cancer Center; license, and research and development collaboration agreement with QIMR Berghofer Medical Research Institute; and strategic collaboration with H. Lee Moffitt Cancer Center. The company was incorporated in 2012 and is headquartered in Thousand Oaks, California.AVROBIONASDAQ:AVROAVROBIO, Inc., a clinical-stage gene therapy company, develops hematopoietic stem cell gene therapies to treat rare diseases in the United States. Its gene therapies employ hematopoietic stem cells that are harvested from the patient and then modified with a lentiviral vector to insert the equivalent of a functional copy of the gene that is mutated in the target disease. The company's pipeline includes AVR-RD-02, which is in phase 1/2 clinical trial for the treatment of Gaucher disease type 1 and 3; AVR-RD-01, which is in phase 2 clinical trials for the treatment of Fabry disease; and AVR-RD-03 that is in preclinical stage for the treatment of Pompe disease. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.AVITA MedicalNASDAQ:RCELAVITA Medical, Inc., together with its subsidiaries, operates as a regenerative medicine company in the United States and internationally. The company's lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds, full-thickness skin defects, and repigmentation of stable depigmented vitiligo lesions. It develops RECELL GO to control the manual process of disaggregation, filtration, and soak time. The company was formerly known as AVITA Therapeutics, Inc. AVITA Medical, Inc. was incorporated in 2020 and is headquartered in Valencia, California.Rubius TherapeuticsNASDAQ:RUBYRubius Therapeutics, Inc., a biopharmaceutical company, focuses on the development of red cell therapeutics for the treatment of cancer and autoimmune diseases. The company was formerly known as VL26, Inc and as changed its name to Rubius Therapeutics, Inc. in 2015. Rubius Therapeutics, Inc. was incorporated in 2013 and is based in Foxborough, Massachusetts. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.